Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 70

  • 16

  • 15

  • 12

  • 10

  • 10

  • 8

  • 7

  • 4

  • 3

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Abstract
Background: Financial toxicity (FT) is reported by up to 50% of cancer survivors and is associated with decline in HRQoL, delaying care and higher mortality. Early data in bladder cancer (BC) suggests the same. Existing data have largely focused on cohorts that have homogeneity in terms of race/ethnicity, insurance type and socioeconomic status. No thresholds for FT in BC have been defined. Hypothesis: Our central hypothesis is that FT is highly prevalent in BC and impacts HR-QoL and treatment decisions. Our secondary hypothesis is that sociodemographic factors will impact the extent and type of FT that is experienced. Methods/Approach: 140 patients with existing BC diagnosis who are receiving treatment at a large, public hospital (site 1) and a tertiary cancer center (site 2) will be recruited to complete validated instruments of (1) financial toxicity/distress, (2) general and disease specific QoL, items pertaining to coping strategies including non-adherence. Clinicopathologic data will be collected from the medical record. 20 patients in each arm who were screened as having FT will undergo semi-structured interviews and this will be synthesized with quantitative data. Concurrent validity between the 2 validated FT measures will be performed and used to generate thresholds of FT associated with risk of decline in HRQoL and non-adherence. A focus group of 8 urologic bladder cancer experts followed by an exploratory survey of 100 urologists, medical oncologists and radiation oncologists will be conducted to assess provider awareness and attitudes. Applicability: FT is a critical factor in these PSN questions and thus necessitates thorough investigation: 1.How does a patient with invasive BC choose between preserving and removing the bladder? 2. How do we improve patient education about expectations for recovery and treatment success after radical cystectomy? 3. How can caregivers of patients with metastatic BC reduce their burdens?

 
188
Projects
USD 101.0 M
Aggregated funding amount
USD 609 K
Average funding amount
Project list item
Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Bladder Cancer Advocacy Network to Sarah Psutka, Jonathan Wright, Daniel Lin, John Gore, Ryan O'Malley, Anne Browning, Florian Fintelmann

USD 50,000
2019 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Biomarker-Based Tools for Treatment Response Decision Support of Bladder Cancer

National Cancer Institute to LUBOMIR M HADJIYSKI, AJJAI SHIVARAM ALVA

USD 653,319
2019 - 2024
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research

National Cancer Institute to KIM N DANFORTH

USD 172,270
2019 - 2021
Project list item
The role of a new molecular driver in bladder cancer

National Cancer Institute to DALEY MORERA

USD 45,016
2018 - 2021
Project list item
Modulation of regulatory T cells in the bladder tumor environment by anti-PD-L1 immunotherapy

Bladder Cancer Advocacy Network to David Yoonsuk Oh, Lawrence Fong

USD 50,000
2018 - 2019
Project list item
Novel 3D personalized bladder cancer model on demand: A new era for personalized medicine.

Canadian Institutes of Health Research to Alan I So, Claudia Itze Chavez-munoz

USD 141,091
2018 - 2020
Project list item
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer

National Cancer Institute to MIKE GLODE, SHAWN PATRICK ZINNEN

USD 299,937
2018 - 2019
Project list item
Recovery Support for Bladder CA Patients and Caregivers: A Multimodal Approach

National Cancer Institute to MICHAEL A DIEFENBACH, SUZANNE M MILLER

USD 722,281
2018 - 2023
Project list item
Intra-operative MRI-guided Robotic System for Photothermal Therapy of Bladder Cancer

University Grants Committee to Kwok Ka Wai, Wong Kenneth Kin Yip, Vardhanabhuti Varut Vince, TEOH Yuen Chun Jeremy

USD 80,682
2018 - 2021
Project list item
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Patient-Centered Outcomes Research Institute to John Gore

USD 8,500,000
2018 - 2022
Project list item
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER

National Cancer Institute to ROSA MARIA DIAZ, BRADLEY C. LEIBOVICH, LUKKANA SUKSANPAISAN

USD 1,081,593
2017 - 2020
Project list item
Improved detection of bladder cancer recurrence using a biophysical biomarker

National Cancer Institute to MICHAEL D HENRY

USD 299,860
2017 - 2019
Project list item
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes

National Cancer Institute to BROCK CLARKE CHRISTENSEN

USD 1,235,254
2017 - 2022
Project list item
Defining the translational landscape of metastatic bladder cancer and its role in therapeutic response to chemotherapy

Bladder Cancer Advocacy Network to Brian Raymond Winters

USD 1,700
2017 - 2017
load more...